

ECHO IDAHO

Substance Use in Idaho

Treating Adult ADHD

Perspectives from Addiction Medicine

4/9/2026

Norman Litchfield, MD, FASAM

Idaho Society of Addiction Medicine

None of the planners or presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.



Disclosures

I do not receive funding from any industry sponsors or research grants

Some slides adapted with permission from Andrea Truncali, MD, MPH; Lauren Moran, MD, MPH; Leah Bauer, MD, FASAM; and Margaret Chaplin, MD, FASAM; ASAM Annual Meeting, Washington, DC; 4/14/23

- No disclosures for Drs Truncali, Bauer and Chaplin. Dr Moran receives funding from NIMH on risk of psychosis and mania with prescription stimulant use (R01 MH122427)

Stimulant treatment for ADHD: Not exactly Opioids 2.0, but close?

Andrea Truncali, MD, MPH, Lauren Moran, MD, MPH,
Leah Bauer, MD, FASAM & Margaret Chaplin, MD, FASAM

American Society of Addiction Medicine Annual Conference
April 14, 2023



Learning Objectives

1. Increase awareness for the complexity involved in accurately diagnosing Attention-Deficit / Hyperactivity Disorder (ADHD) in adults
2. Discuss the evidence for stimulant treatment of adult ADHD alone, and when comorbid with a Substance Use Disorder (SUD)
3. Review the harms associated with stimulant treatment of adult ADHD, including risk of developing a Stimulant Use Disorder (StUD)

Defining Adult ADHD

What is Adult ADHD?


ADHD is a real illness with morbidity as well as substantial cost to society¹

- 3-7% of adults have ADHD^{2,3}, 10-21% in those with SUD⁴
- ADHD is associated w/ increase in:
 - ✓ Unemployment
 - ✓ Car accidents
 - ✓ Mortality
 - ✓ Impaired relationships
 - ✓ SUD (Previously thought that tx of childhood ADHD prevents SUD, but evidence supporting this is mixed⁵)

1. Shein et al, J Manag Care Spec Pharm, 2022
2. DSM-5 TR
3. Song et al, J Glob Health, 2021

4. Rohner et al, Int J Env Res Pub Hlth, 2023
5. Volkow & Swanson, Am J Psychiatry 2008

How is Adult ADHD diagnosed?



5 Symptoms of
Inattention

5 Symptoms of
Hyperactivity

Symptoms
Present < age 12

Symptoms Present
in >2 Domains

Reduced Quality of
(Social or Work) Life

Not due to any other Mental Disorder

Specifiers:

F90.2 Combined presentation

F90.0 Predominantly inattentive
presentation

F90.1 Predominantly
hyperactive/impulsive presentation

Adult ADHD: Extension of childhood, distinct entity or undiagnosed comorbidity?

ADHD persists into adulthood at rates of **5%** (Dunedin cohort) to **30-50%** (MTA cohort)


- Moffitt et al. 2015, Dunedin NZ Cohort: 1,072 individuals born in '72-73, followed until age 38
 - ADHD prevalence: 6% childhood, 3% adult, w/ *“virtually no overlap”*; 3/61 kids w/ ADHD (5%) persisted into adulthood
 - 90% of adults meeting criteria for ADHD lacked h/o childhood ADHD; 55% had SUD
- Sibley et al. 2018, MTA Comparison Cohort: 239 individuals w/o childhood ADHD, followed from ~9yo until ~25yo
 - 95% of those w/o childhood ADHD who screened positive for adult ADHD were subsequently ruled out, most commonly due to effects of substances
- Ahmad et al. 2019, Berkeley Girls w/ ADHD Longitudinal Study, Comparison Cohort: 87 ♀ w/o childhood ADHD, followed 16 yrs
 - Only 1 out of 17 women with adult-onset ADHD sx had no SUD or other MH dx to explain impairment

DSM-5-TR, 2022 (citing Sibley et al. 2018): *“ADHD begins in childhood. [...] When symptoms of what appears to be ADHD first occur after age 13, they are more likely to be explained by another mental disorder or to represent the cognitive effects of substance use.”*

ADHD: Over or Under Diagnosed?

Is it both? The catchphrase “ADHD is over *and* underdiagnosed” began to be used extensively by ADHD lobby in the 1990s in response to rising prevalence rates¹

- There is clear evidence for overdiagnosis
 - Broadening of criteria → higher prevalence of dx and stimulant rx for milder symptoms
 - Tx is less effective for individuals w/ milder symptoms²
 - Children born earlier in school year are diagnosed and treated w/ greater frequency than those born later in the year³
 - US vs International prevalences
- High degree of symptom overlap with SUD and other psychiatric conditions is major cause of misdiagnosis



1. Schwarz, 2016, ADHD Nation (book)
2. Kazda, JAMA Network Open, 2021
3. Layton et al, NEJM, 2018

Malingering and ADHD

- High prevalence of individuals exaggerating symptoms (22% adults)¹
- Evidence that some individuals “fake” ADHD symptoms to obtain stimulant rx²
- Undergraduates coached about ADHD via internet compared to students w/ ADHD³
 - Those coached to fake ADHD met dx criteria for ADHD via symptom checklists
 - Self-rating scales (ie, Connor’s Adult ADHD Rating Scale, Adult ADHD Symptom Rating Scale) particularly susceptible to faking and easily accessible online
- Multiple additional studies corroborate findings that symptom checklists alone are unable to distinguish between malingering and ADHD^{4,5}

1. Marshall et al, Clinical Neuropsychologist, 2010
2. Fuermaier et al, J Neural Transmission, 2021
3. Sollman et al, Psychological Assessment, 2010

4. Quinn CA, Arch Clin Neuropsychol, 2003
5. Booksh et al, J Atten Disorders, 2010

Why is Adult ADHD diagnosis difficult?


- Checklists are usually positive – what is disorder vs what is normal?
- Multiple causes of inattention
 - Other psychiatric disorders (dep/anx, active SUD, PTSD, SPMI)
 - Lifestyle (poor sleep, stress)
 - Multitasking
 - Cannabis use
- No diagnostic test – requires comprehensive evaluation
- People craving substances may feel convinced of the diagnosis and press hard for tx
- Popular diagnosis on social media – hypochondriasis effect

Cannabis and Attention Deficit

- Cannabis use leads to cognitive deficits in several domains^{1,2,3}
 - Executive function, learning and memory, attention, and processing speed
- Deficits persist beyond acute intoxication^{1,3}
- Earlier age of first use is associated w/ more enduring effects on attention in adulthood³
- Following cessation, cognitive recovery can take months, or longer²

1. Dellazizzo et al, Addiction, 2022
2. Ricci et al., Am J on Addictions, 2026
3. Ehrenreich et al, Psychopharmacology, 1999

Addressing ADHD in Primary Care



Evidence for Stimulant Treatment of Adult ADHD

Conflicts of Interest (COI)

- Prominent ADHD researchers who shaped diagnostic and prescribing norms have received significant funding from pharmaceutical companies without disclosing financial ties
 - 2008 US Senate Finance Committee Investigation
 - 2016 Cochrane review on methylphenidate in adults, retracted for COI
- Patient/family advocacy groups receive funding from pharmaceutical companies¹
- Panels responsible for widening definition of ADHD & allowing adult ADHD diagnosis²
 - Majority of members have ties to industry
- Substantial marketing dollars devoted to practicing physicians
 - 25% of all industry payments to pediatricians in 2014 were for 3 stimulant medications³
 - 1 in 18 physicians received marketing from stimulant pharmaceutical companies, most funds (\$7B) for lisdexamfetamine, (2014-2018)⁴

1. Schwarz, ADHD Nation, 2016 (book) 3. Parikh et al., Pediatrics, 2016
2. Moynihan et al., PLOS Medicine, 2013 4. Hadland et al., JAMA Pediatrics, 2020

Cochrane Review, 2018: Amphetamines for Adults

- 19 RCTs using dextroamphetamine, lisdexamfetamine or mixed amphetamine salts
- 18 US studies, 10 multisite
- Mean study length: **5.3 weeks**, range 1-20 weeks
- All placebo-controlled, three also included an active comparator: guanfacine, modafinil or paroxetine
- 16 of 19 studies funded by pharma, 1 publicly funded (Levin 2015, SUD and ADHD), 2 did not disclose funding source

Cochrane Review, 2018: Amphetamines for Adults

- Participants: avg age 35, 57% male, mostly Caucasian, few studies included SUD
- Outcomes reviewed:
 - Severity of ADHD symptoms
 - Retention in treatment
 - Adverse events
- Results: **Low to very low-quality data**
 - Lack of blinding, attrition, selective reporting without *a priori* outline of outcomes, crossover without washout phase, short duration, baseline wellness (extreme validity problem)
 - Symptom severity: clinician rated change of 1-2/7 pts on CGI; 30% ADHD sx reduction on pt rated scales
 - No difference for amphetamine vs guanfacine, modafinil
 - No effect on retention
 - Adverse events: Increased AE-related withdrawals

Cochrane Reviews, 2021,22: Methylphenidate (IR & OROS)

- IR: 10 trials, 487 adults; OROS: 24 trials, 5066 adults
- Similar limitations: short duration (2-3mo), high risk of bias, AE poorly assessed
 - *“Almost all have notable concerns related to sources of funding and conflicts of interest”*
 - Most did not include comorbid psychiatric conditions
 - **Very low-certainty evidence**
- For OROS: no effect on functional outcomes (missed days of work at 13wks) and small-mod effect on self-rated ADHD sx
- For IR, included one direct comparison w/ lithium
 - No difference in MPH vs Li
 - Very low certainty of evidence for a difference compared with placebo on pt and provider rating scales

Evidence Review: Head-to-Head Comparisons

Population	Intervention	Primary Outcome	Notes
N=98, recruited from outpt psych, excluded SUD ¹	Paroxetine vs dexamphetamine (both up to 40mg/day) x20wks	NS difference in ADHD rating scale IV: Dex approx. 4pt (out of 56) lower, but p=0.06	35% lost to f/up (est 20% loss of power), industry funded
N=52, recruited from flyers at psych clinic in Taiwan, open label ²	MPH 10 – 20 TID vs atomoxetine 0.5 – 1.2mg/kg/day, 8-10wks	NS difference in intraindividual variability in reaction time (reduced in both groups)	Mean daily dosages ~30mg MPH, 80mg atomoxetine
N=63, (same grp as above) ³	MPH 10 – 20 TID vs atomoxetine 0.5 – 1.2mg/kg/day, 8-10wks	NS differences in ADHD scales, QOP and Weiss functional improvement scale	ADHD scales: self-report and clinician CGI
N=60 Korean pts on SSRI for MDD w/ only partial response, rater blinded ⁴	OROS MPH vs atomoxetine , titrated to clinical response, 12wks	NS differences in ADHD self-report scale and CGI	Atomoxetine (~59mg M, ~80mg F), MPH (~56mg F, ~59mg M); ASRS and CGI

1. Weiss and Hechtman, J Clin Psychiatry, 2006
 2. Ni et al., J of Psychopharmacology, 2016

3. Ni et al., J Atten Disord, 2017
 4. Shim et al., Clin Psychopharm & Neurosci, 2022

Evidence Review: Functional Outcomes

- In observational studies in adults, stimulant rx associated with:
 - Decreased car accidents¹
 - Decreased unemployment among women, not men²
- They DO NOT improve learning of material or GPA
 - Children randomized to MPH had markedly improved classroom behavior, but no improvement in learning⁴
 - Adherence → 0.11 pt improvement in GPA⁵
- They DO NOT substantially improve performance on neuropsychological testing
 - College students: RCT crossover mixed amphetamine salts vs placebo⁶

1. Chang et al., JAMA Psychiatry, 2017
2. Li et al., JAMA Network Open, 2022
3. Tardelli et al., Psychopharmacology, 2020

4. Pelham et al., Journal of Consulting & Clin Psychology, 2022
5. Marcus et al., J Am Acad CAP, 2011
6. Weyandt et al., Pharmacy, 2018

Harms of Stimulant Treatment for Adult ADHD

Harms: Cardiovascular Risk


- Stimulants increase blood pressure and heart rate
- Observational studies (individuals w/ pre-existing CV disease likely excluded):
 - Non-elderly adults, 25 – 64yrs¹
 - No increased risk of serious CV events (stroke, MI, sudden cardiac arrest / death)
 - Elderly adults, >65yrs²
 - Increased risk of serious CV events (ventricular arrhythmias, stroke)
 - Risk higher within first 30d of starting medication

1. Habel et al., JAMA, 2011
2. Tadrous et al., JAMA Network Open, 2021

Harms: Psychosis

Risk of new onset psychosis:
amphetamines > methylphenidate¹

B Prescription of Stimulant and Number of Psychotic Episodes According to Year of Cohort Entry



Dose dependent increase in first episode
psychosis/mania²

DEX Equivalents	Controls	Cases	Adj OR ±95% CI
None	2,538 (92.9%)	1,170 (87.7%)	Reference
Low: ≤15mg	96 (3.5%)	54 (4.1%)	1.74 (1.13, 2.72)
Medium: 15-30mg	65 (2.4%)	61 (4.6%)	3.54 (2.21, 5.66)
High: >30mg	34 (1.2%)	50 (3.8%)	5.58 (3.21, 9.68)

1. Moran et al., NEJM, 2019
2. Moran et al., Am J Psychiatry, 2024

Harms: Misuse & Addiction

In US adults tx w/ stimulants, **25%** reported misuse, and **~10%** met criteria for StUD¹

- 2019-2022, Data collected from all-payer pharmacy databases and NSDUH
- US adults aged 18 – 64yo
- Among those with prescription StUD, ~75%% solely used their own rx
- Compared to methylphenidate, **amphetamine rx → 3x higher risk for misuse, 2x higher risk for StUD**
- **Risk factors:** never-married; <\$75k/yr; depression; SI; nicotine dependence; alcohol, cannabis, cocaine, methamphetamine, or heroin use; prescription opioid or sedative misuse

Universal precautions to reduce stimulant misuse in treatment for adult ADHD²

- Accurate diagnosis and baseline assessment of RF for misuse
- Educate all patients of abuse potential, safe storage, PDMP review
- For high risk: Use delayed-release preparations, rx small quantities, pill counts, drug screening*
 - ***Many POC Utox may not distinguish between methamphetamine and amphetamine, requiring confirmatory panel to rule out presence of methamphetamine when prescribing amphetamines**

1. Han et al., JAMA Psychiatry, 2025
2. Modesto-Lowe et al., Cleveland Clinic J Medicine, 2015

Harms: Mortality / Overdose

Off-label prescribing in adults is rising, associated w/ increased all-cause mortality compared to on-label prescribing¹

One observational study of people on BUP for OUD, prescribed stimulant therapy²

- Associated with:
 - 19% inc chance of non-fatal overdose
 - 36% increase in treatment retention
- Selection bias: only included pts w/ high adherence to stimulants

1. Westover et al., Addiction, 2018
2. Mintz et al., JAMA Network Open, 2022

Updated FDA Black Box Warning, 5/11/2023

To address continuing concerns of **misuse**, **addiction** and **overdose** of prescription stimulants, FDA required updates to the Boxed Warning across the entire class

What should healthcare professionals do?

- ✓ Assess pts for risk of misuse, abuse and addiction before prescribing stimulants
- ✓ Counsel pts not to share prescribed stimulant with anyone
- ✓ Educate patients and families on serious risks, proper storage and proper disposal
- ✓ Regularly reassess and monitor for s/sx of non-medical use, addiction, and diversion

Stimulant Use Disorder

DSM-5 Criteria for SUD

≥2 items in 12mo period

1. Using more or longer than intended
2. Cannot cut down
3. ↑ time spent obtaining, using, recovering
4. Cravings
5. Failure to fulfill responsibilities
6. Social or interpersonal problems
7. Give up / reduce other important activities
8. Ongoing use in hazardous situations
9. Ongoing use despite known problems
10. Tolerance
11. Withdrawal

Specifiers:

Mild: 2-3 criteria

Moderate: 4-5 criteria

Severe: ≥6 criteria

- In early remission: no crit ≥3mo**
- In sustained remission: no crit ≥12mo**
- On maintenance therapy*
- In a controlled environment*

*w/ exception of cravings

DSM-5 Criteria for SUD

≥2 items in 12mo period

1. Using more or longer than intended
2. Cannot cut down
3. ↑ time spent obtaining, using, recovering
4. Cravings
5. Failure to fulfill responsibilities
6. Social or interpersonal problems
7. Give up / reduce other important activities
8. Ongoing use in hazardous situations
9. Ongoing use despite known problems
10. Tolerance
11. Withdrawal

Loss of Control

Specifiers:

Mild: 2-3 criteria

Moderate: 4-5 criteria

Severe: ≥6 criteria

- In early remission: no crit ≥3mo**
- In sustained remission: no crit ≥12mo**
- On maintenance therapy*
- In a controlled environment*

*w/ exception of cravings

DSM-5 Criteria for SUD

≥2 items in 12mo period

1. Using more or longer than intended
2. Cannot cut down
3. ↑ time spent obtaining, using, recovering
4. Cravings
5. Failure to fulfill responsibilities
6. Social or interpersonal problems
7. Give up / reduce other important activities
8. Ongoing use in hazardous situations
9. Ongoing use despite known problems
10. Tolerance
11. Withdrawal

**Social
Impairment**

Specifiers:

Mild: 2-3 criteria

Moderate: 4-5 criteria

Severe: ≥6 criteria

- In early remission: no crit ≥3mo**
- In sustained remission: no crit ≥12mo**
- On maintenance therapy*
- In a controlled environment*

*w/ exception of cravings

DSM-5 Criteria for SUD

≥2 items in 12mo period

1. Using more or longer than intended
2. Cannot cut down
3. ↑ time spent obtaining, using, recovering
4. Cravings
5. Failure to fulfill responsibilities
6. Social or interpersonal problems
7. Give up / reduce other important activities
8. Ongoing use in hazardous situations
9. Ongoing use despite known problems
10. Tolerance
11. Withdrawal

Risky Use

Specifiers:

Mild: 2-3 criteria

Moderate: 4-5 criteria

Severe: ≥6 criteria

- In early remission: no crit ≥3mo**
- In sustained remission: no crit ≥12mo**
- On maintenance therapy*
- In a controlled environment*

*w/ exception of cravings

DSM-5 Criteria for SUD

≥2 items in 12mo period

1. Using more or longer than intended
2. Cannot cut down
3. ↑ time spent obtaining, using, recovering
4. Cravings
5. Failure to fulfill responsibilities
6. Social or interpersonal problems
7. Give up / reduce other important activities
8. Ongoing use in hazardous situations
9. Ongoing use despite known problems
10. Tolerance
11. Withdrawal

*Physiologic Dependence**

Specifiers:

Mild: 2-3 criteria

Moderate: 4-5 criteria

Severe: ≥6 criteria

- In early remission: no crit ≥3mo**
- In sustained remission: no crit ≥12mo**
- On maintenance therapy*
- In a controlled environment*

*w/ exception of cravings

Trends in StUDs

Dramatic, disproportionate increases in mortality relative to use¹

- Between 2015-2019, methamphetamine use **↑43%**, overdose deaths **↑180%**
- Reflects riskier consumption patterns
 - Increased injection use
 - Co-use with opioids (particularly fentanyl-contaminated supplies)
 - Higher frequency of use
- By 2021, **50% of all US overdose deaths involved stimulants**²

Significant demographic disparities persist in stimulant-associated fatalities

- From 2009-2018, cocaine-associated death rate among non-Hispanic Black individuals was nearly double that of non-Hispanic White individuals³

1. Han et al., JAMA Psychiatry, 2021
2. Batki et al., AAAP Guideline, 2023
3. Das, Kutscher, JAMA Health Forum, 2020

ASAM/AAAP Treatment Guideline, 2024

Behavioral Treatment: **Contingency management** (CM) has demonstrated the best effectiveness and represents the current standard of care (*H,S*)

- Additional interventions to be considered alongside CM: Community Reinforcement Approach, CBT, Matrix Model

Pharmacotherapy for Amphetamine-type StUD:

- Non-psychostimulant medication
 - Bupropion, bupropion & naltrexone, topiramate, mirtazapine (*L-M,C*)
- Psychostimulant medication
 - ***Only for board-certified addiction medicine specialists w/ “commensurate training, competencies and capacity for close patient monitoring... including pill counts, drug testing, frequent clinical contact and frequent PDMP checks”***
 - “Can consider prescribing a long-acting methylphenidate formulation to promote reduced use of amphetamine type stimulants” (*L,C*)

ASAM/AAAP Treatment Guideline, 2024


Concurrent Management of StUD and ADHD

- Clinicians should address ADHD symptoms as part of the treatment of StUD
 - Consider stimulants for ADHD when benefits outweigh the risks (*L,S*)
 - Prescribe non-stimulant medications for ADHD when benefits of stimulants do not outweigh the risks (*L,S*)
 - Atomoxetine, bupropion, guanfacine, clonidine, venlafaxine
 - Encourage behavioral approaches (*L,S*)
- When prescribing psychostimulants for co-occurring ADHD and StUD
 - Use extended-released formulations (*CC,S*)
 - Maintain a level of monitoring commensurate with the risk profile for the given medication and patient (*CC,S*)
 - Pill counts, drug testing, more frequent clinical contact, more frequent PDMP checks

RCT: Mirtazapine for Methamphetamine Use Disorder

POPULATION

213 Male, 126 Female



Adults with moderate to severe methamphetamine use disorder
Mean (SD) age, 42.0 (8.6) y

SETTINGS / LOCATIONS



6 Outpatient clinics in Australia

INTERVENTION

344 Participants randomized



172 Mirtazapine
Mirtazapine, 30 mg/d for 12 wk




172 Placebo
Matched placebo

PRIMARY OUTCOME

Change in self-reported days of methamphetamine use in the past 28 d from baseline to week 12 (possible range, 0-28 d of the past 28 d). Self-reported days of methamphetamine use was assessed at baseline and wk 4, 8, and 12.

FINDINGS

The mirtazapine group had a greater reduction in days of methamphetamine use in the past 28 d from baseline to wk 12 than the placebo group



Difference in days of methamphetamine use:

Mirtazapine group: -7.0 d; 95% CI, -8.5 to -5.6

Placebo group: -4.8 d; 95% CI, -6.3 to -3.4

Mean group difference: -2.2 d; 95% CI, -4.2 to -0.2; $P = .02$

Wrap Up

Key Takeaways

- Adult ADHD carries significant morbidity, with higher prevalence among people w/ SUD
- Diagnosing adult ADHD is complex and time consuming
- The evidence for benefit of treatment with stimulants consists of numerous low-quality studies without functional outcomes
 - **Risk of non-stimulant treatment is lower – and benefit may be comparable to stimulants in terms of functional outcomes**
- Risks associated with stimulant treatment include misuse, addiction, overdose, psychosis, and CV events
 - **Risk may be mitigated by universal precautions, including careful diagnosis and monitoring**

Questions?

References, pt 1

- Ahmad SI, et al. 2019. Little evidence for late-onset ADHD in longitudinal sample of women. *J Consulting and Clin Psych*, 87(1):112-117.
- American Psychiatric Association. 2022. *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision, DSM-5-TR*.
- Boeson K, et al. 2022. Extended-release MPH for ADHD in adults. *The Cochrane Database of Systematic Reviews*, 2(2), CD012857.
- Booksh RL, et al. 2010. Ability of college students to simulate ADHD on objective measures of attention. *Journal of Attention Disorders*, 13(4) 325-338.
- Bourgeois FT, et al. 2014. Premarket safety and efficacy studies for ADHD medications in children. *PLoS One*, 9(7):e102249.
- Candido RCF, et al. 2021. Immediate-release MPH for ADHD in adults. *The Cochrane Database of Systematic Reviews*, 1(1), CD013011.
- Carpentier JP, Levin FR. 2017. Pharmacologic treatment of ADHD in addicted patients: what does the literature tell us? *Harvard Review of Psychiatry*, 25(2) 50-64.
- Castells X, et al. 2018. Amphetamines for ADHD in adults. *The Cochrane Database of Systematic Reviews*, 8(8), CD007813.
- Chang Z, et al. 2017. Association between medication use for ADHD and risk of motor vehicle crashes. *JAMA Psychiatry*, 74(6):597-603.
- Cipriani A, et al., 2018. Unbalanced risk-benefit analysis of ADHD drugs – Authors’ reply. *The Lancet Psychiatry*, 5(11):871-873.
- Cook J, et al. 2017. Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review. *Aust N Z J Psychiatry*, 51(9):876–885.
- Cortese S, et al. 2018. Comparative efficacy and tolerability of medications for ADHD in children, adolescents and adults: a systematic review and network meta-analysis. *The Lancet Psychiatry*, 5(9):727-738.
- Curran HV, et al. 2016. Keep off the grass? Cannabis, cognition and addiction. *Nature Reviews Neuroscience*, 17(5):293-306.
- Das LT, Kutscher E. 2020. Stimulant Use Disorders in the United States – Is another epidemic on the horizon? *JAMA Health Forum*, 1(12):e201486
- Ehrenreich H, et al. 1999. Specific attentional dysfunction in adults following early start of cannabis use. *Psychopharmacology*, (142)295-301
- Faltisen EG, et al. 2018. Unbalanced risk-benefit analysis of ADHD drugs. *The Lancet Psychiatry*, 5(11):870.
- Fuermaier ABM, et al. 2021. Feigning ADHD and stimulant misuse among Dutch university students. *Journal of Neural Transmission (Vienna, Austria: 1996)*, 128(7):1079-1084.
- Habel LA, et al. 2011. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA*, 306(24):2673-2683.
- Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. 2021. Methamphetamine use, use disorder and associated overdose deaths among US adults. *JAMA Psychiatry*. 78(12):1329-1342.
- Han B, Jones CM, Volkow ND, et al. 2025. Prescription stimulant use, misuse, and use disorder among US adults aged 18 to 62 years. *JAMA Psychiatry*. Mar 19:e250054.
- Hadland SE, et al. 2020. Analysis of pharmaceutical industry marketing of stimulants, 2014 through 2018. *JAMA Pediatrics*, 174(4):385-387.
- Huang H, et al. 2020. Approach to evaluating and managing ADHD in primary care. *Harvard Review of Psychiatry*, 28(2), 100-106.
- Katz N. 2007. Opioids: After thousands of years, still getting to know you. *The Clinical Journal of Pain*, 23(4):303-306.
- Kazda L, et al. 2021. Overdiagnosis of ADHD in children and adolescents: a systematic scoping review. *JAMA Network Open*, 4(4), e21535.
- Layton TJ, et al. 2018. ADHD and month of school enrollment. *The New England Journal of Medicine*, 379(22):2122-2130.

References, pt 2

- Li L, et al. 2022. Association between pharmacological treatment of ADHD and long-term unemployment among working-age individuals in Sweden. *JAMA Network Open*, 5/(4):e226815
- Marshall P, et al. 2010. Effectiveness of symptom validity measures in identifying cognitive and behavioral symptom exaggeration in adult ADHD. *The Clinical Neuropsychologist*, 24(7), 1204-1237.
- McKretin R, Shoptaw S, Saunders L et al. 2026. Mirtazapine for methamphetamine use disorder: a randomized clinical trial. *JAMA Psychiatry*. Published online April 1, 2026.
- Mintz CM, et al., 2022. Analysis of stimulant prescriptions and drug-related poisoning risk among persons receiving buprenorphine treatment for opioid use disorder. *JAMA Network Open*, 5(5),e2211634.
- Miller N. 2025. Amphetamines: a current epidemic. *Front. Psychiatry*. 16:1460341
- Modesto-Lowe V, et al. 2015. Universal precautions to reduce stimulant misuse in treating adult ADHD. *Cleveland Clinic Journal of Medicine*, 82(8)506-512.
- Moffitt TE, et al. 2015. Is Adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. *The American Journal of Psychiatry*, 172(10), 967–977.
- Moran LV, et al. 2019. Psychosis with methylphenidate or amphetamine in patients with ADHD. *The New England Journal of Medicine*, 380(12)1128-1138.
- Moran LV, et al. 2024. Risk of incident psychosis and mania with prescription amphetamines. *Am J Psychiatry*. 181(10):901-909.
- Moynihan RN, et al. 2013. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the US. *PLoS Medicine*, 10(8):e1001500.
- Ni HC, et al. 2016. Atomoxetine could improve intra-individual variability in drug-naïve adults with ADHD comparably with MPH: A head-to-head RCT. *Journal of Psychopharmacology (Oxford, England)*, 30(5), 459-467.
- Ni HC, et al. 2017. An open-label, randomized trial of MPH and atomoxetine tx in adults with ADHD. *Journal of Attention Disorders*, 21(1), 27-39.
- Özgen H, et al. 2020. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. *Eur Addict Res*. 26(Suppl. 4-5):223–232.
- Parihk K, et al. 2016. Industry relationships with pediatricians: findings from the open payments sunshine act. *Pediatrics*, 137(6) e21054440.
- Pelham WE, et al. 2022. The effect of stimulant medication on the learning of academic curricula in children with ADHD: a randomized crossover study. *J Consult Clin Psychol*, 90(5):367-380.
- Piper BJ, et al. 2018. Trends in use of prescription stimulants in the US and territories, 2006 to 2016. *PLoS One*, 13(11)e0206100.
- Quinn CA. 2003. Detection of malingering in assessment of adult ADHD. *Archives of clinical neuropsychology: The Official Journal of the National Academy of Neuropsychologists*, 18((4), 379-395.
- Ricci V, Fraccalini T, Martinotti G, Maina G, 2026. Cannabis cessation and neurocognitive recovery: Patterns, predictors, and clinical implications – a systematic review. *Am J on Addictions*. Published online 23 March 2026
- Rohner H, et al. 2023. Prevalence of ADHD among SUD populations: Meta-analysis. *International Journal of Environmental Research and Public Health*, 20(2)1275.
- Schwarz A. 2016. *ADHD Nation: Children, Doctors, Big Pharma, and the Making of an American Epidemic*. Simon & Schuster.
- Shein J, et al. 2022. Economic burden of ADHD among adults in the US: a societal perspective. *Journal of Managed Care & Specialty Pharmacy*, 28(2)168-179.
- Shim SH, et al. 2022. Comparison between atomoxetine and OROS MPH as an adjunctive to SSRIs in ADHD adults with comorbid partially responsive MDD: A head-to-head, 12wk, randomized, rater-blinded clinical trial. *Clinical Psychopharmacology and Neuroscience: The Official Scientific Journal of the Korean College of Neuropsychopharmacology*, 20(1), 143- 153.

References, pt 3

- Sibley MH, et al & the MTA Cooperative Group. 2018. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. *The American Journal of Psychiatry*, 175(2)140-149.
- Singh I. 2008. Beyond polemics: Science and ethics of ADHD. *Nat Rev Neurosci*, 9:957-964.
- Singh J. 2015. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. *J Pharmacol Pharmacother*. Jul-Sep;6(3):185-7.
- Sollman MJ, et al. 2010. Detection of feigned ADHD in college students. *Psychological Assessment*, 22(2), 325-335.
- Song P, et al. 2021. The prevalence of adult ADHD: A global systematic review and meta-analysis. *Journal of Global Health*, 11, 04009.
- Tadrous M, et al., 2021. Assessment of stimulant use and cardiovascular event risks among older adults. *JAMA Network Open*, 4(10):e2130795.
- Tardelli VS, et al. 2020. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. *Psychopharmacology*, 237(8), 2233-2255.
- Urits I, et al. 2021. Adverse Effects of Recreational and Medical Cannabis. *Psychopharmacol Bull*. 51(1):94-109.
- Volkow ND, Swanson JM. 2008. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? *The American Journal of Psychiatry*, 165(5)553-555.
- Volkow ND, et al. 2014. Adverse health effects of marijuana use. *New England Journal of Medicine*, 370(23):2219-27.
- Wang S, Zheng Y. 2018. Unbalanced risk-benefit analysis of ADHD drugs. *The Lancet Psychiatry*, 5(11):870-871.
- Warren JB. 2018. Unbalanced risk-benefit analysis of ADHD drugs. *The Lancet Psychiatry*, 5(11):871.
- Weis M, Hechtman L, et al., 2006. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for ADHD in adults. *The Journal of Clinical Psychiatry*, 67(4), 611-619.
- Westover AN, et al., 2018. Risk of amphetamine use disorder and mortality among incident users of prescribed stimulant medications in the Veterans Administrations. *Addiction*, 113(5),887-867,
- Weyandt LL, et al. 2018. Neurocognitive, autonomic and mood effects of Adderall: a pilot study of healthy college students. *Pharmacy*, 6(3), 58.
- Zaso MJ, Park A, Antshel KM. 2020. Treatments for Adolescents With Comorbid ADHD and Substance Use Disorder: A Systematic Review. *J Atten Disord*, 24(9):1215–1226.